Clinical trials have started for China's fourth COVID-19 vaccine, developed by the National Vaccine and Serum Institute under the China National Biotec Group (CNBG). Since the outbreak, the CNBG has allocated one billion yuan (about 141.29 million U.S. dollars) for vaccine development.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3